Literature DB >> 28228052

Inhalation therapy in patients with tracheostomy: a guide to clinicians.

Arzu Ari1, James B Fink1.   

Abstract

INTRODUCTION: Inhalation therapy has become a popular procedure for the treatment of patients with tracheostomy. However, clinicians are faced with many challenges during inhalation therapy because of the many factors affecting aerosol therapy to this patient population, and the lack of literature providing guidance in this area of research. Areas covered: The purpose of this paper is to describe the factors affecting aerosol drug delivery to patients with tracheostomy and to explain how to optimize inhalation therapy through device selection, interface selection and delivery technique in this patient population. Expert commentary: Many factors affect inhalation therapy in this patient population and without understanding the impact of these factors on aerosol drug delivery, clinicians will not be able to provide the treatment properly and patients may not benefit from prescribed medications. In the next 5 years, aerosol medicine will continue to experience tremendous growth with new devices and drug/device combinations. However, these advances will have minimal impact on inhalation therapy in patients with tracheostomy unless we provide guidance and training to clinicians on optimizing aerosol drug delivery to this patient population.

Entities:  

Keywords:  Aerosols; drugs; mechanical ventilation; metered-dose inhalers; nebulizers; tracheostomy

Mesh:

Substances:

Year:  2017        PMID: 28228052     DOI: 10.1080/17476348.2017.1289843

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  1 in total

1.  Aerosol Characteristics and Physico-Chemical Compatibility of Combivent® (Containing Salbutamol and Ipratropium Bromide) Mixed with Three Other Inhalants: Budesonide, Beclomethasone or N-Acetylcysteine.

Authors:  Rui Zhang; Junhua Hu; Liangjun Deng; Sha Li; Xi Chen; Fei Liu; Shanping Wang; Khaja Shameem Mohammed Abdul; Huimin Beng; Wen Tan
Journal:  Pharmaceutics       Date:  2020-01-17       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.